Hercules Development Group / Astralis LLC

Plaque psoriasis

Disease Overview

Plaque psoriasis is a chronic, immune-mediated inflammatory skin disease characterized by accelerated keratinocyte proliferation and T-cell-driven plaque formation, affecting roughly 3% of US adults. Severity ranges from mild localized disease to severe systemic involvement with associated psoriatic arthritis and cardiometabolic comorbidities.

Competitive Landscape

In late 2001 the systemic psoriasis market was dominated by methotrexate, cyclosporine and oral retinoids (Soriatane), with the first biologics era just beginning — Amgen's Enbrel (etanercept, TNF inhibitor) had recently launched in rheumatology and was being explored for psoriasis (FDA-approved for plaque psoriasis 2004), Genentech/Biogen Idec's Raptiva (efalizumab, anti-CD11a, approved 2003 then withdrawn 2009 for PML), and Centocor/J&J's Remicade (infliximab) and Amevive (alefacept, Astellas/Biogen, approved 2003) were in late development. Astralis LLC's Psoraxine — a peptide/protein immunostimulant claimed to reverse rather than suppress psoriatic inflammation, with prior open-label data in 3,000 Venezuelan patients reporting 96% response and 638 complete remissions — entered the public markets via reverse merger into the Hercules Development real-estate shell on November 13, 2001 (~$110.6M Hercules stock-deal value plus $3.2M PIPE; https://www.bioworld.com/articles/475256). The thesis collapsed when Psoraxine missed its Phase II primary endpoint vs placebo in March 2005, halving Astralis's stock and effectively ending the program; the company never advanced a Phase III. The deal stands as a cautionary marker of early-2000s shell-merger biotech vehicles built on uncontrolled foreign data.